Accurus Biosciences and ImmPACT Bio Enter into an Exclusive Global License Agreement for a Potentially Best-in-Class CLDN18.2 Antibody January 25, 2024
Boehringer Ingelheim And 3T Biosciences Enter Into A Second Partnership To Develop Next-Generation Cancer Immunotherapies January 10, 2024
Innate Pharma Announces Licensing Of A Fourth Natural Killer Cell Engager In Oncology To Sanofi January 10, 2024
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics January 10, 2024
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio January 10, 2024
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases January 10, 2024
Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Clinical Stage CDK2 Inhibitor From Allorion Therapeutics January 10, 2024
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted ADC January 10, 2024
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs January 10, 2024
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program December 19, 2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform December 19, 2023
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) December 19, 2023
FDA guides on the next Ph 2 study for advancement of Next Generation Capecitabine (“NGC-Cap”) for cancer patients December 19, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma December 11, 2023
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio December 11, 2023
